Search
Trametinib
go.drugbank.com/drugs/DB08911ApprovedInvestigationalOriginally developed by Japan Tobacco, trametinib was initially investigated for treating inflammation, but further studies for this indication were not pursued.[A258298] … [A258298] It was later approved by Health Canada on July 18, 2013 [L45588] and by the European Commission on June 30, 2014.
Bacillus calmette-guerin substrain russian BCG-I live antigen
go.drugbank.com/drugs/DB16648ApprovedInvestigational[L32734] It is to be marketed by Verity Pharmaceuticals, under the trade name VERITY-BCG, and manufactured by the Serum Institute of India. … It was developed to alleviate Canada's multi-year shortage of BCG vaccine, and is expected to be available by mid-2021.[L32734]
Arbutin
go.drugbank.com/drugs/DB11217ApprovedExtracted from the dried leaves of bearberry plant in the genus Arctostaphylos and other plants commonly in the Ericaceae family, arbutin is a beta-D-glucopyranoside of DB09526. It is found in foods, over-the-counter drugs, and herbal di...
Mixtures: Dr G Whitening REFORMER by EGF, Dr G Whitening FORTIFIER by EGFTeicoplanin
go.drugbank.com/drugs/DB06149ApprovedInvestigationalWithdrawnAll teicoplanins share a same glycopeptide core, teicoplanin A3-1, but differ in the length and conformation of side chains attached to their β-D-glucosamine moiety.
Cidofovir
go.drugbank.com/drugs/DB00369ApprovedInvestigational[FDA label] It was manufactured by _Gilead_ and initially approved by the FDA in 1996, but has since been discontinued.[L6223]
Maraviroc
go.drugbank.com/drugs/DB04835ApprovedInvestigationalIt was originally labelled as UK-427857 during development but was assigned the Maraviroc name as it entered trials. It was approved for use by the FDA in August, 2007. … Maraviroc (brand-named Selzentry, or Celsentri outside the U.S.) is a chemokine receptor antagonist drug developed by the drug company Pfizer that is designed to act against HIV by interfering with the
Vaborbactam
go.drugbank.com/drugs/DB12107ApprovedInvestigationalVaborbactam is added to the therapy to reduce the extent meropenem degradation by inhibiting the serine beta-lactamases expressed by the microorganism of target. … In August 2017, a combination antibacterial therapy under the market name Vabomere was approved by the FDA for the treatment of adult patients with complicated urinary tract infections (cUTI).
Leflunomide
go.drugbank.com/drugs/DB01097ApprovedInvestigationalLeflunomide was approved by FDA and in many other countries (e.g., Canada, Europe) in 1999.
Ethchlorvynol
go.drugbank.com/drugs/DB00189ApprovedIllicitWithdrawnIt has been used to treat insomnia, but has been largely superseded and is only offered where an intolerance or allergy to other drugs exists.
Isocarboxazid
go.drugbank.com/drugs/DB01247Approved[T115] It was first introduced by Roche pharmaceuticals, further developed by Validus pharms Inc and first FDA approved as a prescription drug on July 1st, 1959.